Goettingen, Germany, July 19, 2014 --(PR.com
)-- MVA Technology
A drop of human blood is presumed to have 10e11 specific antibodies that recognize different immunogens (natural antigen epitopes and antigenic mimics, mimotopes). Although the potential size of the human immunoglobulin repertoire has been estimated, the understanding of its overall involvement in the immune response has remained elusive, mainly because researchers are not yet able to decipher it. MVA technology has overcome that problem. Protobios' novel technology platform, Mimotope Variation Analysis (MVA, patent pending), for parallel and quantitative profiling of the binding specificity, versatility and biological activity of millions of antibodies, reflects the total immune response.
MVA technology enables to obtain quantitative and qualitative antibody binding profiles (immunoprofiles). A binding profile can be made to describe a single molecule up to individuals or populations. An immunoprofile describes the state of the immune system and its ability to protect the body. That is considered an innovative tool interpreting health related data for diseases and health conditions and propels the caregivers towards a new level of understanding regarding prevention and treatment. Also, MVA allows offering reliable services such as epitope mapping, antibody analyses, immunogenicity assessment, etc. to research groups and the biotechnology industry.
MVA technology is based on screening of combinatorial peptide display library, next generation DNA sequencing and proprietary bioinformatics analysis.
Epitope mapping defines the binding specificity of an antibody. Protobios’s Mimotope Variation Analysis (MVA) technology gives a detailed description of epitopes and mimotopes and has several advantages over other technologies.
In a standard MVA Epitope mapping protocol, three million antibody-captured peptides from the peptide display library will be analyzed and clustered. In general, monoclonal antibody analysis will result in one epitope, whereas polyclonal antibody analysis may result in numerous epitopes.
The immunogen competition assay (ICA) is a recommended procedure for confirming the epitope-specific binding activity of antibodies. The ICA provides means to discriminate between true and non-specific (crossreactive)
targets for the antibody.
Advantages of MVA Based Epitope Mapping:
• Precise – Identifies and distinguishes all, including overlapping, epitopes.
• Quantitative and qualitative – Epitope description includes Positional Weight Matrix of amino acid residues in the peptide epitope motif.
• Universal – No need for prior knowledge of the immunogen.
• Cost effective – Saves money compared to competing techniques, such as peptide array.
Protobios is an Estonian biotechnology company founded in October 2003, and is positioning itself as a developer of new diagnostic tests and also as a service provider in the field of immunome analysis.
Throughout our history, we have contributed to the development of new technologies in the field of cell biology and immunology. We will continue to maintain our focus, today and tomorrow, on novel solutions and will always be interested to learn more from others, in order to combine joint expertise that will help lead us to the next series of inventions.
MoBiTec GmbH (Goettingen, Germany) is a privately held company (founded in 1987) that offers research tools for molecular and cell biology. Products include DNA vectors for cloning and expression, cell transfection reagents and cell culture tools, immobilized and soluble enzymes, products for genomics and proteomics research, numerous antibodies and recombinant proteins, superior fluorescence reagents and kits, affinity chromatography products, as well as general laboratory equipment.
In parallel to its own product lines, MoBiTec distributes products from international companies in Germany. MoBiTec products are distributed worldwide, in Germany from their home office, in other countries by distributors.